NCT07072325

Safety, Tolerability, PK, and Efficacy of CD-001 in Advanced Head & Neck Cancers

A Clinical Study Assessing the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CD-001 in Patients With Advanced Head & Neck Cancers

• Status: Not Yet Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 9 (estimated)
• Sponsor: West China Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The goal of this prospective, single-center, open-label, dose-escalation study is to evaluate the safety, tolerability, and preliminary efficacy of CD-001 in patients with advanced head and neck cancers who have experienced disease progression (PD) or intolerance to standard systemic therapy (or lack thereof). The main question\[s\] it aims to answer: * What is the safety and tolerability profile of CD-001 across escalating doses? * What is the preliminary efficacy of CD-001 in this patient population?

Conditions

• Malignant Neoplasm
• Head &Amp; Neck Cancer
• Head and Neck Cancer
• Advanced Head and Neck Carcinoma

Interventions

Type	Name	Description
DRUG	CD-001	CD-001 administered as an intravenous (lV)infusion.

Timeline

• Start date: 2025-08-10
• Primary completion: 2027-08-01
• Completion: 2028-08-31
• First posted: 2025-07-18
• Last updated: 2025-08-03